BridgeMD
Tests treatment safety and results for Myocardial Infarction (MI)
Official title Efficacy of Montelukast on STEMl Patients
ClinicalTrials.gov ID: NCT07320625
What this study is testing
What is Montelukast?
Montelukast is an investigational medicine, being studied as a potential treatment for myocardial infarction (mi).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Acute myocardial infarction (AMI) is one of the leading causes of patient mortality worldwide. Each year, over 8 million people globally die from AMI, with approximately 30% of these cases being ST-segment elevation myocardial infarction (STEMI).
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age \> 18 years and \< 75 years;
- Diagnosed with acute anterior ST-segment elevation myocardial infarction and planned to undergo primary percutaneous coronary intervention;
- Time from symptom onset ≤ 12 hours;
- The patient and their family members voluntarily participate in this study and sign the informed consent form.
You likely can't join if
- Cardiogenic shock, severe heart failure (Killip Class IV), or structural complications such as papillary muscle rupture;
- Having received cardiopulmonary resuscitation ;
- Severe and inadequately controlled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg);
- Severe liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding three times the upper limit of normal) or...
- History of myocardial infarction;
- Concomitant active bleeding or visceral hemorrhage;
See the full eligibility criteria
- Age \> 18 years and \< 75 years;
- Diagnosed with acute anterior ST-segment elevation myocardial infarction and planned to undergo primary percutaneous coronary intervention;
- Time from symptom onset ≤ 12 hours;
- The patient and their family members voluntarily participate in this study and sign the informed consent form.
- Cardiogenic shock, severe heart failure (Killip Class IV), or structural complications such as papillary muscle rupture;
- Having received cardiopulmonary resuscitation ;
- Severe and inadequately controlled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg);
- Severe liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding three times the upper limit of normal) or renal dysfunction (estimated glomerular filtration rate (eGFR) \< 30...
- History of myocardial infarction;
- Concomitant active bleeding or visceral hemorrhage;
- Concomitant malignant tumors, lymphomas, leukemias, or other diseases with an expected survival time of less than 1 year;
- Having undergone gastrointestinal surgery within the past 4 weeks that may affect the absorption of the investigational drug;
- Pregnant or breastfeeding women;
- Family history of psychiatric disorders;
- Having been enrolled in another drug study within the past 4 weeks or currently receiving any investigational treatment other than the study drug;
- Allergic to montelukast or having used montelukast within the past 4 weeks;
- Unable to tolerate cardiac magnetic resonance imaging (e.g., patients with magnetic materials in the body or those with claustrophobia).
The study team makes the final eligibility decision.
Where it's taking place
- Dalian, Liaoning, China
- Shanghai, Shanghai Municipality, China
- Dalian, China
- Fuzhou, China
- Guangdong, China
- Ha’erbin, China
- Hefei, China
- Hunan, China
- Shenyang, China
- Wenzhou, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dalian, Liaoning, China; Shanghai, Shanghai Municipality, China; Dalian, China; Fuzhou, China; Guangdong, China; Ha’erbin, China and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.